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Anorexia nervosa (AN) is a severe psychiatric disorder with high rates of morbidity, comorbidity and mortality, which in
a subset of patients (21%) takes on a chronic course. Since an evidence based treatment for AN is scarce, it is crucial to
investigate new treatment options, preferably focused on influencing the underlying neurobiological mechanisms of
AN. The objective of the present paper was to review the evidence for possible neurobiological correlates of AN, and
to hypothesize about potential targets for Deep brain stimulation (DBS) as a treatment for chronic, therapy-refractory
AN. One avenue for exploring new treatment options based on the neurobiological correlates of AN, is the search for
symptomatologic and neurobiologic parallels between AN and other compulsivity- or reward-related disorders.
As in other compulsive disorders, the fronto-striatal circuitry, in particular the insula, the ventral striatum (VS)
and the prefrontal, orbitofrontal, temporal, parietal and anterior cingulate cortices, are likely to be implicated in
the neuropathogenesis of AN. In this paper we will review the few available cases in which DBS has been performed in
patients with AN (either as primary diagnosis or as comorbid condition). Given the overlap in symptomatology and
neurocircuitry between reward-related disorders such as obsessive compulsive disorder (OCD) and AN, and the
established efficacy of accumbal DBS in OCD, we hypothesize that DBS of the nucleus accumbens (NAc) and
other areas associated with reward, e.g. the anterior cingulated cortex (ACC), might be an effective treatment
for patients with chronic, treatment refractory AN, providing not only weight restoration, but also significant and
sustained improvement in AN core symptoms and associated comorbidities and complications. Possible targets for
DBS in AN are the ACC, the ventral anterior limb of the capsula interna (vALIC) and the VS. We suggest conducting
larger efficacy studies that also explore the functional effects of DBS in AN.
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Anorexia Nervosa (AN) is a severe psychiatric disorder
characterized by an intense fear of gaining weight com-
bined with a failure to maintain a minimally normal body
weight (85% of the expected standard for age and height/
ideal body weight). Patients with AN have a disturbed
body image, are obsessed with weight and body shape,
and are in a state of a denial with regard to their low body
weight and its adverse impact on health (American Psy-
chiatric Association 2006, 2000; Diagnostic and Statistical
Manual of Mental Disorders 1994). In a subgroup of pa-
tients AN is associated with characteristic compulsive* Correspondence: ddenys@gmail.com
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reproduction in any medium, provided the orbehaviors such as dieting, exercise, and/or purging with or
without binge eating. Amenorrhea is often present in fe-
male patients but no longer required for the diagnosis
(DSM 5, American Psychiatric Association 2013). With a
narrow age of onset, a stereotypic presentation of symp-
toms and course, and a relative gender specificity AN is
possibly the most homogenous of all psychiatric disorders.
The average point prevalence rate of AN is 0.3% in young
females [1,2] and the lifetime prevalence is 2.2% among
females [3]. The condition largely affects young adoles-
cent females, with a female–male ratio between 10:1
and 4:1 [1,4].Medical complications
AN is often associated with medical complications resulting
from starvation, purging and/or over exercising. Common
signs and symptoms include cardiovascular complicationsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypotension, loss of subcutaneous fat tissue, impaired
menstrual function, hair loss, and hypothermia [5]. With
improved nutritional status or with remittance of abnor-
mal eating and purging behaviours, most pathophysio-
logical complications are reversible. Nevertheless, some
physical consequences of AN can be life-threatening,
such as electrolyte imbalances, severe bradycardia, and
hypotension. Moreover, nutritional deficiencies may in-
crease the risk of cardiac arrhythmias and intercurrent in-
fection. Some medical consequences of eating disorders
may be irreversible or have later serious consequences on
health, especially osteoporosis, growth retardation, mal-
functioning of the reproductive system and neurobio-
logical changes of the brain caused by malnutrition [6,7].
Mortality, course and comorbidity
AN is associated with the highest rate of mortality
among all mental disorders, with a crude mortality rate
of 5,9% and a mortality rate of 5,6% per decade [8,9].
Other studies found mortality rates in the same range
[10-15]. Steinhausen found a mean crude mortality rate
of 5,0% [11]. Causes of death ranged from eating dis-
order complications to suicide. The majority of individ-
uals with eating disorders reported suicidal thoughts and
about 22% attempt to commit suicide [16,17].
In an extensive literature review Steinhausen showed
that less than half (46,9%) of the surviving patients re-
cover on average from AN, one-third (33,5%) improve
partially, and in 20,8% (0-79%) the disease takes on a
chronic course [11]. It had to be noted that the criteria
used to define recovery and chronicity are very diver-
gent. The studies reviewed, vary considerably in duration
of follow-up (1–29 years), whereas outcome is influ-
enced significantly by the duration of follow-up, with a
higher mortality but also a tendency towards recovery
with increasing duration of follow-up in surviving pa-
tients [11]. On the other hand, chronicity is associated
with poor outcome, indicating that some cases of AN
are indeed treatment refractory [18]. For the purpose of
this article, we chose to define chronicity as an illness
duration of five years or more.
Patients with AN have elevated rates of lifetime diagno-
ses of anxiety disorders, depressive disorders, obsessive-
compulsive disorder (OCD), personality disorders and
substance abuse disorders [6,7,18]. Comorbidity in eating
disorders is substantial and contributes to a less favorable
outcome of AN.
Treatment options
The therapeutic options for AN consist of different
treatment-approaches that focus on weight restoration,
changes in behaviour and reducing the psychological
features of AN. However, evidence-based treatment forAN is very limited. There is no category A evidence and
only family interventions meet category B criteria ac-
cording to the NICE-guidelines [19-22].
Psychotherapeutic interventions include cognitive be-
havioural therapy (CBT) and family therapy. A number
of studies have reported that CBT after weight restor-
ation could be effective in reducing the risk of relapse in
adults with AN, but it is unknown what the efficacy is in
underweight patients (see [23] for review). Variants of
family therapy show a modest level of evidence with re-
gard to efficacy in adolescents but not in adults.
SSRIs are ineffective in reducing AN symptoms or re-
storing weight and the American Psychiatric Association
does not support the use of SSRIs in the management of
underweight patients with AN [23] (Treatment of pa-
tients with eating disorders, APA 2006). There is some,
however weak, evidence that the use of SSRIs may help
in preventing relapse in weight restored patients [24,25].
Tricyclic antidepressants seem ineffective on weight gain
or improvement of AN symptoms [26,27]. For atypical an-
tipsychotics, there are only limited data available [28]. Bis-
sada et al. conducted a double-blind, placebo-controlled
trial in 34 patients with AN. Olanzapine treatment re-
sulted in more rapid weight gain and improvement in ob-
sessive symptoms [29]. Two other randomized, controlled
trials with olanzapine showed similar results [30,31]. An-
other study, conducted in an inpatient setting, failed to
show any benefit for olanzapine on weight and psycho-
logical symptoms [32]. These results indicate that olanza-
pine may be helpful in increasing weight and decreasing
obsessive symptoms in chronic severe AN in outpatients
[33], but practice guidelines do not recommend its routine
use [34,35] (American Psychiatric Association 2006).
Unfortunately, there is no agreement on the definition
of treatment-refractoriness in AN [36]. Refractory AN is
a term used in clinical psychiatry to describe cases of
AN not responding to typical modes of treatment, such
as psychotherapy and psychopharmacology. Strober
et al. (1997) and Herzog et al. (1999) found that the pos-
sibility of recovery in AN patients with an illness dur-
ation longer than 10 years is very low [37,38].
Review
Etiopathology of AN
The pathophysiology of AN remains unknown. It is un-
clear whether there is a primary disturbance of appetite,
or whether the disturbed appetite is secondary to other
phenomena, such as body image disturbance, or anxiety
[39]. The aetiology of eating disorders is considered multi-
factorial, with involvement of genetic factors [40-45],
neurobiological factors, and temperamental vulnerabil-
ities such as negative emotionality, poor intraceptive
awareness, perfectionism and obsessive-compulsive person-
ality traits [41,46-48], that may interact with environmental
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biology and neurocircuitries involved in AN are a main
focus in today’s AN research. Of particular interest are the
brain areas involved in registering the reward value and
modulation of reward of food and the motivation to eat,
considered to be located within the mesolimbic cortex and
striatum [50,51]. Moreover, the brain areas involved in the
cognitive control of eating and appetite, located in the
dorsolateral prefrontal and parietal cortices may be in-
volved in AN [39,49].
Neurotransmitters
Results from positron-emission tomography (PET) studies
indicate differences between subjects recovered from AN
and healthy subjects in serotonin and dopamine receptor
activity, indicating dysregulation of these systems involved
in mood, anxiety, appetite and impulse control [39,52].
Several studies showed alterations in the serotonergic
(5-HT)-system in AN. For example, Kaye et al. (2009)
reported elevated 5-HT metabolite levels, as well as ele-
vated binding potential for postsynaptic 5-HT1a recep-
tors and diminished binding potential for 5-HT2a
receptors in recovered AN patients [53-55]. In contrast,
ill AN patients were shown to have reduced amounts of
the major 5-HT metabolite, 5-hydroxyindoleacetic acid
(5-HIAA) [39]. Finally, it has been found that a dietary-
induced reduction of tryptophan, the precursor of
serotonin, is associated with decreased anxiety in AN
patients [56]. Starvation may help AN patients to
briefly reduce 5-HT activity and thus give symptom
relief.
These alterations in 5-HT function may be related to
AN symptoms regarding inhibition of appetite, general-
ized inhibition, anxiety and obsessions through stimula-
tion of 5-HT1a receptors.
Several studies showed that ill and recovered AN pa-
tients also have altered striatal dopamine (DA) function.
Kaye et al. (1999) found reduced levels of DA metabo-
lites in the cerebrospinal fluid in ill and recovered AN
patients [57]. Frank et al. (2005) found that patients re-
covered from AN had increased D2/D3 receptor binding
potential in the ventral striatum (VS), indicating either
increased D2/D3 receptor density or decreased extracel-
lular DA, or both [58]. In addition, functional DA D2 re-
ceptor gene polymorphisms have been associated with
AN [59] and subjects with AN have impaired visual dis-
crimination learning, indicating altered DA neurotrans-
mission in AN [60].
Disturbances in the DA-system may contribute to an al-
tered response to reward and alterations in decision-
making and executive control found in patients with AN.
Similar alterations of 5-HT and DA function are also
found in other reward-related disorders like OCD, although
the exact mechanisms and the interactions betweenthese and other neurotransmitter systems are not clari-
fied yet [61].
Neuroimaging
Imaging studies showed that in the acute phase of AN,
patients have a reduced brain volume and enlargement
of the cortical sulci and the ventricles [62-64]. Alter-
ations in activity in the insula and the prefrontal, orbito-
frontal, temporal, parietal and anterior cingulate cortices
and the VS at rest and during symptom provocation
were found [65-71]. These alterations may however be
contributed to malnourishment and are mostly revers-
ible with weight restoration.
However, functional imaging studies conducted in pa-
tients recovered from AN possibly reflect trait-related
rather than state-related changes which could be an in-
dication of the possible underlying neurobiological
mechanisms in AN [72-74]. Several studies reported
hypoperfusion of temporal, parietal, occipital and frontal
regions in AN patients not correlated to their BMI
[75-77]. It has also been reported that remitted as well
as non-remitted AN patients have increased activations
in brain regions implicated in the reward system (the
medial prefrontal cortex and anterior cingulated cortex
(ACC)) in response to food stimuli [78]. In a study of
Wagner et al. (2007) no difference was found in ventral
striatal response discriminating between positive and
negative feedback in recovered AN patients, suggesting
an impairment to identify the emotional significance of
stimuli and the involvement of the brain reward sys-
tem. Recovered AN patients also showed exaggerated
activation of the caudate-dorsal striatum region and the
dorsolateral prefrontal and parietal cortex, regions con-
cerned with planning and consequences [79]. Zastrow
et al. (2009) showed that impaired behavioral set shifting
in AN is associated with hypoactivation in the ventral
anterior cingulate-striato-thalamic loop and with hy-
peractivation of frontoparietal networks [80]. Another
study by Wagner et al. (2008) showed a reduced BOLD
signal response to sucrose in the anterior insula, the
ACC and the striatum, indicating an altered incentive
processing in the anterior insula [81]. All these studies
implicate the involvement of the fronto-striatal cir-
cuitry in the neuropathogenesis of AN.
The insula is thought to be implicated in taste and its
incentive value, interoceptive awareness and fear [49].
The ACC is associated with emotional processing, body
image, self-monitoring, conflict resolution, and reward-
based decision making [72,78,82]. The parietal lobe is
functionally associated with disturbed body image and
the low or absent insight in their condition, two of the
core features of AN [67,72]. It is hypothesized that dis-
turbances in interoceptive awareness, impairments of
the ventral striatal pathways and an enhanced cognitive
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sating for primary deficits in limbic function) are in-
volved in the pathogenesis of AN [39].
Because of the involvement of the reward-related neu-
rocircuitries described above, the areas communicating
between the limbic and the cortical systems, such as the
nucleus accumbens (NAc) and the cingulate and insular
cortices [39,83] may be of particular interest as possible
target areas for future neurosurgical interventions.
Deep brain stimulation
Deep brain stimulation (DBS) is an innovative and promis-
ing approach for the treatment of patients with treatment-
refractory reward-related psychiatric disorders [84-87]. DBS
is a reversible and adjustable neurosurgical treatment involv-
ing the implantation of electrodes that send electrical im-
pulses to specific locations in the brain, selected according
to the type of symptoms to be addressed and its putative
neuroanatomical correlates [88,89].
Our center has experience with DBS in OCD, addic-
tion, and major depressive disorder. In all these disor-
ders, DBS targets reward related brain areas such as the
NAc and the ventral capsule/ventral striatum (VC/VS).
Target selection has evolved based on clinical results
from earlier ablative procedures and DBS-studies, neuro-
imaging studies and theoretical considerations regarding
the implicated neurocircuitries involved in these disor-
ders [84,86,87,90]. The current working hypothesis is
that DBS inhibits or functionally overrides pathological
network hyperactivity in several treatment-resistant psy-
chiatric disorders. Our research group showed efficacy
for DBS in OCD targeted at the NAc normalizing NAc
activity, reducing excessive connectivity between the
NAc and prefrontal cortex, and decreasing frontal low-
frequency oscillations during symptom provocation in
patients with OCD. These findings taken together sug-
gest that DBS is able to reduce maladaptive activity and
connectivity of the stimulated region and to restore
disease-related brain networks to a healthy state [91].
To consider a psychiatric disorder as a possible new
indication for DBS and a particular patient as candidate
Denys (2008) suggested the following criteria [92]:
Disorder-related criteria:
(a)A general agreement on the neuropsychiatric nature
of the disorder.
(b)A proven relationship with a dysfunctional brain circuitry.
(c)Objectively measurable symptoms.
Patient-related criteria:
(a)Presence of very severe symptoms and considerable
suffering.(b)Absence of available effective treatments.
(c)Potential to regain reasonable functioning and
integration in society.
DBS in AN
Considering 1) the clear neurobiological correlates of
the disorder, 2) the homogeneity of the disorder, 3) the
severity of AN, its complications and high mortality
rates, 4) the fact that AN takes on a chronic course in a
considerable percentage of patients and the fact that, up
to date, evidence based treatment for AN is very limited,
it is crucial to investigate new treatment options for AN
that focus on influencing the underlying neurobiological
mechanisms of the disease rather than focus on weight
restoration alone. In this review article we want to
propose DBS as a possible new treatment option for pa-
tients with chronic, treatment-resistant AN.
For a long time, neurosurgery targeted at various brain
areas (mostly leucotomy) has been considered a last re-
sort treatment for AN. While reviewing the literature on
neurosurgical procedures in AN, we found most articles
reported weight gain and sometimes other symptomatic
improvements. However, there was much heterogeneity
as well as missing data on patient selection, follow-up
and outcome measurements. Therefore, clinical outcome
appears at least to us, somewhat inconclusive [93-101].
In a case-report of Barbier et al. (2011) a successful an-
terior capsulotomy in comorbid AN and OCD is de-
scribed, resulting in normalization of eating pattern and
weight and a significant decrease of food-related obses-
sive compulsive symptoms after three months [102].
To date, there are very limited data on the effect of
DBS in the treatment of AN. There are two case reports,
a case series of four patients and a pilot study published
on DBS in AN (see Table 1). Israël et al. (2010) described
a patient treated with DBS in the subgenual cingulate
cortex, part of the ACC, for severe refractory depression,
whose co-morbid eating disorder showed lasting remis-
sion, consisting of a normalisation of BMI (19,1 kg/m2)
and Eating Attitudes Test-26 at 2-year follow-up. It must
be noted that pre-surgery this patient also had periods
of (partial) recovery from her eating disorder, and that
her BMI pre-surgery was 20,9 kg/m2 [103]. A more re-
cent case report by McLaughlin (2012) described im-
provements in AN symptoms following DBS of the VC/
VS for intractable OCD [104]. The first study (case
series) on DBS in AN was conducted by Sun et al. from
the Shanghai group. Preliminary results reported an
average of 65% increase in body weight at 38-month
follow-up in four adolescent patients with AN treated
with DBS of the NAc, showing that DBS might be a
valuable option for weight-restoration in AN [105]. Very
recently, Lipsman et al. (2013) published the results of a
phase-1 pilot trial of subcallosal cingulate (ACC) DBS in
Table 1 DBS in AN
Study n DBS target Result
Israel (2010) 1 Subgenual cingulate cortex DBS for treatment resistant major depression. Co morbid eating disorder-NOS in
lasting remission (normalisation of scores on the Eating Attitudes Test-26 and
Eating Disorders Examination; normalisation of weight (BMI 19,1 kg/m2) at 2 and
3 year follow-up)
McLaughlin (2012) 1 Ventral capsule/ventral
striatum
DBS for treatment resistant OCD. Improvements in AN symptoms consisting of
less distress about caloric intake and weight (assessment tools and length of
follow-up not mentioned; BMI pre-surgery 18,5 kg/m2, post-surgery 19,6 kg/m2)
Sun et al. in Wu et al. (2012) 4 Nucleus accumbens Average of 65% increase in body weight at 38-month follow-up (average baseline
BMI: 11,9 kg.m2; average BMI at follow-up: 19,6 kg/2); restoration of the menstrual
cycle (n = 4); regaining school functioning (n = 3); remission of AN according to
the DSM-IV (n = 4)
Lipsman et al. (2013) 6 Subcallosal cingulate Relatively safe (1 serious adverse event), improvement of BMI compared to
historical baseline (n = 3) at 9 month follow-up (average baseline BMI: 13,7 kg/m2;
average BMI pre-surgery: 16,1 kg/m2; average BMI at 9 month follow-up: 16,6 kg/m2).
Improvements in mood, anxiety, affective regulation and anorexia-related obsessions
and compulsions (the latter assessed with the Yale-Brown-Cornell eating disorder
scale) at 6 month follow-up; Improvements in quality of life (n = 3)
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found that DBS was relatively safe in this population and
found to result in improvements of mood, anxiety,
affective regulation and anorexia-related obsessions and
compulsions in four patients. Furthermore, at a 9 month
follow up period improved BMI’s compared to the esti-
mated historical baseline BMI’s in three patients were
found [101,106].
Possible DBS targets for AN
As stated before, many parallels can be drawn with re-
gard to symptoms of AN and OCD [107]. Moreover,
there is a considerable overlap between the neurocircuits
implicated in OCD and eating disorders, suggesting a
possible etiological relationship between the two disor-
ders. Both disorders consist of repetitive thoughts and
preoccupations about a feared stimulus, followed by a
negative emotion, than followed by compensatory behav-
iours. Like OCD, AN can be considered a compulsivity
disorder. Compulsivity encompasses the repetitive, irre-
sistible urge to perform a behavior, the experience of loss
of voluntary control over this intense urge, the dimin-
ished ability to delay or inhibit thoughts or behaviors,
and the tendency to perform repetitive acts in a habitual
or stereotyped manner [108]. Research showed that AN
is associated with impairments in set shifting and behav-
ioural response shifting [80,109]. Furthermore, there is a
high rate of comorbidity between eating disorders and
anxiety disorders [110-112]. Kaye et al. reported that
41% of AN patients have a lifetime diagnosis of OCD
[111]. Alterations in the activity of cortico-thalamo-
striatal circuits similar to those found in OCD and other
compulsivity disorders have commonly been found in
AN, as described above [39,72,113-115].
Given the similarities in symptomatology and associated
neurocircuits between OCD and AN, the establishedefficacy of DBS in OCD [87], and the neurobiological cor-
relates of AN as described above, we hypothesize that
DBS of the NAc and other areas associated with reward,
e.g. the ACC, might be effective in patients with
chronic, treatment refractory AN, providing not only
weight restoration, but also significant and sustained
improvement in AN core symptoms and associated co-
morbidities and complications. Possible targets for
DBS in AN are the ACC, the ventral anterior limb of
the capsula interna (vALIC) and the VS (consisting of
the ventral caudate nucleus and the NAc).
Suggestions for in- and exclusion criteria
As DBS in AN is an experimental treatment whose effi-
cacy still needs to be established, it would be logical to
initially include only patients with a chronic course who
are treatment-resistant and have a poor prognosis. As
stated before, there has thus far been no agreement on
the definitions of recovery and treatment-refractoriness in
AN [35]. We suggest to define treatment-refractoriness as a
lack of response to two or more typical modes of treatment,
including one hospital admission or inpatient treatment in
a clinic specialized in the treatment of eating disorders, and
an illness duration of five years or more. We suggest inclu-
sion and exclusion criteria for studies investigating the effi-
cacy of DBS in AN similar to those suggested by Wu et al.
(2012) and Lipsman et al. (2013) [105,106]:
Inclusion criteria
 Primary diagnosis: Anorexia Nervosa (restricting or
purging type) according to the DSM-IV criteria
based on a psychiatric interview.
 Chronicity, defined by an illness duration > 5 years.
 Disabling severity with substantial functional
impairment according to the DSM-IV criterion C
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of 45 or less for at least two years.
 Treatment refractoriness, defined as lack of response
to two or more typical modes of treatment,
including one hospital admission or inpatient
treatment in a specialized clinic.
 Weight <85% of ideal body weight (and/or BMI < 17,5).
 Age: 21–65 years old.
 Able to fully understand the consequences of the
procedure capable to make his or her own choice
without coercion and able to give written informed
consent.
Exclusion criteria
 Unstable physical condition (severe electrolyte
disturbances, cardiac failure, other physical
contraindications for surgery/anesthesia).
 A treatable underlying cause of anorexia/
underweight.
 An active neurological disease like Parkinson’s
disease, dementia, tic disorder or epilepsy.
 Schizophrenia/history of psychosis, bipolar disorder.
 Alcohol or substance abuse (including
benzodiazepines) during the last 6 months.
 Antisocial personality disorder.
 Standard MRI scan exclusion criteria (pregnancy,
pacemaker and metals contraindicated for MRI
except for the DBS implantation and stimulator
itself ).
Safety considerations
In general, potential risks involved in DBS include the
risks associated with the surgical procedures, including
the small risk (< 1%) of intracranial haemorrhage or in-
fection and the associated neurological consequences
[116]. In addition, some patients may show some tem-
porary neurological symptoms (e.g. eye movement ab-
normalities) that generally disappear spontaneously or
after some fine-tuning of the stimulator.
Patients with AN are predisposed to significant risk of
multi-organ dysfunction related to starvation and pur-
ging. This can have implications on mortality and mor-
bidity associated with anesthetic complications during
DBS implantation [117]. Therefore, a thorough pre-
operative anaesthetic assessment and evaluation is re-
quired to assist the planning of safe peri-operative care.
Patients should be rehydrated adequately and any de-
ranged electrolyte levels should be corrected pre-
operatively. There is an increased risk of intra-operative
hypothermia. Therefore measures should be taken to
keep the patient warm during surgery. Doses of most
(anaesthetic) drugs should be adjusted for weight. Pa-
tients are particularly susceptible to nerve palsies due totheir cachexia and loss of cushioning subcutaneous tis-
sue. Therefore they must be placed carefully on the op-
erating table. During the operation, ECG-changes and
potassium levels should be monitored carefully to minimize
the risk of arrhytmias. To minimize the overall increased
risks associated with anaesthesia the weight and somatic
condition will be maximally optimized prior to surgery.
Lipsman et al. (2013) reported several adverse events
in their pilot study on DBS in AN, with one serious
DBS-related adverse event (seizure during programming)
and the other serious adverse events being related to the
underlying illness. One patient in this study developed
hypophospataemia and a refeeding delirium [106]. It is
expected that weight increase following treatment with
DBS will be gradual rather than sudden and excessive.
Other DBS studies, for example in OCD and depression,
showed that improvement of symptoms takes several
months [85-87,106]. However, in case of rapid weight
gain following successful treatment with DBS, there is a
risk of development of a refeeding syndrome [118].
Therefore, AN patients treated with DBS should be ad-
vised to increase their food intake gradually and under
supervision of a dietary consultant. The somatic condi-
tion and the potential development of a refeeding syn-
drome should be closely monitored by a physician.
Conclusions
AN is a serious psychiatric disorder with high rates of
morbidity, comorbidity and mortality, that takes on a
chronic course in a considerable percentage of patients.
Since evidence-based treatments are scarce, it is crucial
to investigate treatment options based on underlying
neurobiological mechanisms of the disease.
The fronto-striatal circuitry, in particular the insula,
the VS and the prefrontal, orbitofrontal, temporal, par-
ietal and anterior cingulate cortices, appear to be impli-
cated in the etiopathogenesis of AN. Thus, the areas
communicating between the limbic and the cortical sys-
tems, such as the NAc and the cingulate and insular cor-
tices may be of interest as target areas for future
neurosurgical interventions.
DBS had the advantage over ablative neurosurgery in
being reversible and adjustable and studies show that
DBS is able to reduce maladaptive activity and connect-
ivity of the stimulated region and to restore disease-
related brain networks to a healthy state. Given the
overlap in symptomatology and associated neurocir-
cuits between reward-related disorders like OCD and
AN, and the established efficacy of accumbal DBS in
OCD, we hypothesize that DBS of the NAc and other
areas associated with reward, e.g. the ACC, might be
an effective treatment for patients with chronic, treat-
ment refractory AN, providing not only weight restor-
ation, but also significant and sustained improvement
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and complications. Possible targets for DBS in AN are
the ACC, the vALIC and the VS (consisting of the ven-
tral caudate nucleus and the NAc).
Larger studies with primary outcome aimed at sus-
tained core symptom reduction and weight restoration
are necessary. Preferably, studies should be conducted
with a double blind cross-over design with active and
sham stimulation. Furthermore, functional effects of DBS
in AN should be explored by evaluating neuropsycho-
logical parameters and by using neuroimaging techniques.
In our opinion, the seriousness of the disorder and the
clear neurobiological substrates of AN justify consider-
ing an invasive procedure like DBS as a treatment-
option for chronic, treatment-refractory AN. When
carefully selecting the stimulation target, using clear
in- and exclusion criteria and closely monitoring the
safety aspects of DBS in this population, and in the
meanwhile thoroughly investigating the clinical and
functional effects, DBS could be promising in attacking
the core symptoms of AN and contribute to the know-
ledge of the intriguing pathophysiological mechanisms
of AN.
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